In the next couple of weeks, Phase3 data of two COVID19 vaccines tested by Indian manufacturers are expected to be submitted for emergency use approval. If even one of the vaccines gets the approval, a countrywide rollout to immunise the four high-risk groups starting with healthcare workers will begin soon thereafter. India has been vaccinating millions of young children with a variety of vaccines each year and hence has the entire system in place to roll out any new vaccine under the universal immunisation programme.
But this is the first time a vaccine to be administered outside the programme and specifically for adults is to be rolled out. Since several aspects of the COVID19 vaccination programme are new — vaccinating millions of adults belonging to specific groups, administering two doses of the vaccine a few weeks apart, and the process of enrolling the recipients and rolling out the immunisation programme — the government has rightly decided to undertake a dry run for vaccine administration. The dry run is expected to be initiated this week in four States — Andhra Pradesh, Assam, Gujarat, and Punjab.
It will allow the administrators to test the vaccination process and check the usage of the CoWIN IT platform for the management of the entire vaccination process including data entry, allocation of date and time and a drill of session sites with test beneficiaries. The linkages between planning, implementation and reporting mechanisms will also be tested. Since four high-risk groups have been prioritised to receive the vaccine, the first task is to register the recipients on the CoWIN platform. Unlike vaccinating children under the universal immunisation programme, the COVID19 vaccine will be administered to 100 adults at each designated site on a predefined date and time.
Prior to vaccination, the bonafide of the registered adults are to be determined. The IT platform has to generate the date and time when people can receive the second dose. When more than one vaccine becomes available, it is essential to ensure that people receive the same vaccine twice. Checking and reporting of all adverse events immediately and days after the vaccination is essential, all the more as no COVID19 vaccine has undergone long term followup for safety during the trial. Both the vaccines that are at an advanced stage of testing in India do not require ultralow temperature for delivery and storage.
Hence, the existing facilities of the universal immunisation programme in most districts can be used for storing the vaccines. As the plan is to vaccinate 300 million people in the four high-risk groups, 600 million doses will be required. This exercise should therefore look at creating additional storage capacity at these facilities to store millions of COVID19 vaccines, as facilities for vaccine storage cannot be dedicated to a single vaccine.
Read More Latest Bollywood Movie Reviews & News
Read More Sports News, Cricket News
Read More Latest Mobile, Laptop News & Review